PTO/SB/05 (01-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to re

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

	spond to a collection of inform	ation unless it displays a valid OMB control numb	oer.
	Attorney Docket No.	13/113	
	First Inventor	Montse Llinas-Brunet	
	Title	Hepatits C Inhibitor Compound	
	Evoress Mail Lahel No	EL 989311244 US	

See MPEP o	APPLICATION ELEMENTS chapter 600 concerning utility patent application contents.	ADDRESS TO: Commission P.O. Box 1	Patent Application oner for Patents 450 VA 22313-1450			
(Submit 2. Applica See 37 3. Specifi (preferr - Descr - Cross - Stater - Referr or a ca - Backg - Brief 3	ransmittal Form (e.g., PTO/SB/17) t an original and a duplicate for fee processing) ant claims small entity status. 7 CFR 1.27. ication [Total Pages	ii. 🔽 Paper	Form (CRF) The control of above copies			
- Claim		ACCOMPANYING AP	PLICATION PARTS			
4. Drawin 5. Oath or Dec a. Nev b. Cop (for i. 4. Appli 18. If a CONTII specification fol	laration [Total Sheets] laration [Total Sheets] why executed (original or copy) by from a prior application (37 CFR 1.63(d)) continuation/divisional with Box 18 completed) DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). ication Data Sheet. See 37 CFR 1.76 NUING APPLICATION, check appropriate box, and supplication to title, or in an Application Data Sheet under 3.	or its Other or its or	nt Attorney			
Prior application in	nformation: Examiner	Art Unit:				
For CONTINUATION OR DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.						
19. CORRESPONDENCE ADDRESS						
Custom	ner Number: 28513	OR Correspondence address below				
Name						
Address						
		State	Zip Code			
		elephone	Fax			
Name (Print/Type) Philip I. Datlow Registration No. (Attorney/Agent) 41,482						
Signature	All has		Date March 3, 2004			

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

385 Request for Continued Examination (RCE)

SUBTOTAL (3) (\$)

900 Request for expedited examination

of a design application

to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond

CEE TO A NOMITTAL			Complete if Known					
FEE TRANSMITTA	니	Application Number		lumbe	Not Yet Assigned			
for FY 2004		Filing Date			March 5 , 2004			
		First Named Inventor		Invent	or Montse Llinas-Brunet			
Effective 10/01/2003. Patent fees are subject to annual revision.		Examiner Name		me	Not Yet Assigned			
Applicant claims small entity status. See 37 CFR 1.27		Art Unit			Not Yet Assigned	Not Yet Assigned		
TOTAL AMOUNT OF PAYMENT (\$) 1094.00		Attorr	ney Doc	ket No	o. 13/113			
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)							
Check Credit card Money Other None	3. ADDITIONAL FEES							
Deposit Account:	<u>Large</u>	Large Entity Small Entity						
Donosit	Fee Cod	Fee e (\$)		ee (\$)	Fee Description	Paid_		
Account Number	1051		2051		Surcharge - late filing fee or oath	21 414		
Deposit Account Boehringer Ingelheim Corporation		50	2052		Surcharge - late provisional filing fee or			
Name	1053	130	1053		cover sheet Non-English specification			
The Director Is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments	1812	2,520	1812 2	,520 F	or filing a request for ex parte reexamination			
Charge any additional fee(s) or any underpayment of fee(s)	1804	920*	1804		Requesting publication of SIR prior to			
Charge fee(s) indicated below, except for the filing fee	1805	1.840°	1805 1		Examiner action Requesting publication of SIR after			
to the above-identified deposit account.		·		E	Examiner action			
FEE CALCULATION	1251		2251		Extension for reply within first month			
1. BASIC FILING FEE	1252		2252		Extension for reply within second month			
Large Entity Small Entity Fee Fee Fee Fee Fee Paid Fee Description Fee Paid	1253		2253		Extension for reply within third month			
Code (\$) Code (\$)		1,480	2254		Extension for reply within fourth month			
1001 770 2001 385 Utility filing fee 770.00		2,010	i		Extension for reply within fifth month	t		
1002 340 2002 170 Design filing fee	1401		2401		Notice of Appeal			
1003 530 2003 265 Plant filing fee	1402 1403		2402 2403		Filing a brief in support of an appeal Request for oral hearing			
1004 770 2004 385 Reissue filing fee		1,510	ŀ		Petition to institute a public use proceeding			
	1452	•	2452		Petition to revive - unavoidable			
SUBTOTAL (1) (\$) 770.00		1,330	2453		Petition to revive - unintentional			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		1,330	2501		Utility issue fee (or reissue)			
Fee from Ext <u>ra Claims below Fee Paid</u>	1502	480	2502		Design issue fee			
Total Claims 38 -20** = 18 X 18.00 = 324.00 Independent 1 -3** = 0 X 86.00 = 0.00		640	2503	320	Plant issue fee			
		130	1460	130	Petitions to the Commissioner			
Multiple Dependent 290.00 =	1807	50	1807	50 1	Processing fee under 37 CFR 1.17(q)	l		
Large Entity Small Entity Fee Fee Fee Fee Fee Description	1806	180	1806		Submission of Information Disclosure Stmt	 -∤		
Code (\$) Code (\$)	8021	40	8021	40 F	Recording each patent assignment per property (times number of properties)			
1202 18 2202 9 Claims in excess of 20 1201 86 2201 43 Independent claims in excess of 3	1809	770	2809	385 F	Filing a submission after final rejection			
1201 86 2201 43 Independent claims in excess of 3 1203 290 2203 145 Multiple dependent claim, if not paid	1810	770	2810		(37 CFR 1.129(a)) For each additional invention to be			
1204 86 2204 43 ** Reissue independent claims					examined (37 CFR 1.129(b))			

**or number prev	iously paid, if greater; For Reissues, see a	above Reduced by Basic Filing	g Fee Pald	SUBTOT	AL (3) (\$)	
SUBMITTED BY				(Complet	te (if applicable))	
Name (Print/Type)	Philip I. Datlow	Registration No. (Attorney/Agent)	41,482	Telephoi	ne 203-798-4542	
Signature	1001	6		Date	March 3, 2004	

1801

1802

324.00

770

900

Other fee (specify)

2801

1802

*Reduced by Basic Filing Fee Paid

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

** Reissue independent claims over original patent

** Reissue claims in excess of 20 and over original patent

(\$)

1204

1205

86

2204

2205

SUBTOTAL (2)

APPLICANT(S):

Montse Llinas-Brunet

SERIAL NO.:

Not Yet Assigned

CONFIRMATION NO.:

Not Yet Assigned

FILING DATE:

March 1, 2004

DOCKET NO.:

13/113

TITLE:

Hepatitis C Inhibitor Compound

- 1. Utility Patent Application Cover Sheet (1 pg);
- 2. Fee Transmittal FY 2004 (1pg, In Triplicate);
- 3. Application Data Sheet (2 pgs);
- 4. Specification (77 pgs);
- 5. Sequence Listing (paper only: 1 pg)

Date Mailed: March 3, 2004

"EXPRESS MAIL" LABEL NO.: EL 989311244 US

DEPOSIT DATE: March 3, 2004

I HEREBY CERTIFY THAT THE ABOVE PAPERS AND FEE ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO:

Commissioner for Patents Mail Stop Patent Application P. O. Box 1450 Alexandria, VA 22313-1450

Philip I. Datlow Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT 06877-0368

Tel: (203) 798-4542 Date: March 3, 2004